ACAD
32.86
+0.56
+1.73%
AEMD
5.3
-0.05
-0.93%
APRI
0.34
0.00
-0.15%
ARNA
1.63
0.00
0.00%
ATEC
3.692
+0.092
+2.556%
CNAT
1.9
-0.04
-2.06%
CRXM
0.168
0.00
0.00%
CYTX
2.05
+0.02
+0.99%
DXCM
91.24
+0.62
+0.68%
GNMK
8.75
+0.01
+0.11%
HALO
9.82
+0.27
+2.83%
ILMN
172.21
+2.73
+1.61%
INNV
0.27
-0.13
-32.50%
INO
8.86
+0.19
+2.19%
ISCO
1.95
0.00
0.00%
ISIS
57.56
0.00
0.00%
LGND
103.55
-0.1
-0.10%
LPTN
2.75
-0.07
-2.48%
MBVX
5.07
-0.02
-0.34%
MEIP
1.91
-0.07
-3.54%
MNOV
6.17
-0.25
-3.89%
MRTX
5.09
+0.11
+2.21%
MSTX
0.39
-0.01
-1.49%
NBIX
49.54
+0.6
+1.23%
NUVA
64.07
+0.68
+1.07%
ONCS
1.7
-0.02
-1.16%
ONVO
3.88
-0.02
-0.51%
OREX
3.85
+0.03
+0.79%
OTIC
16.01
+0.33
+2.10%
QDEL
21.59
+0.17
+0.79%
RCPT
231.96
0.00
0.00%
RGLS
3.24
+0.08
+2.53%
RMD
69.03
+0.59
+0.86%
SPHS
3.52
+0.02
+0.57%
SRNE
6.62
+0.06
+0.91%
TROV
5
+0.08
+1.63%
VICL
3.99
+0.14
+3.64%
VOLC
18
0.00
0.00%
ZGNX
9.29
+0.21
+2.31%
ACAD
32.86
+0.56
+1.73%
AEMD
5.3
-0.05
-0.93%
APRI
0.34
0.00
-0.15%
ARNA
1.63
0.00
0.00%
ATEC
3.692
+0.092
+2.556%
CNAT
1.9
-0.04
-2.06%
CRXM
0.168
0.00
0.00%
CYTX
2.05
+0.02
+0.99%
DXCM
91.24
+0.62
+0.68%
GNMK
8.75
+0.01
+0.11%
HALO
9.82
+0.27
+2.83%
ILMN
172.21
+2.73
+1.61%
INNV
0.27
-0.13
-32.50%
INO
8.86
+0.19
+2.19%
ISCO
1.95
0.00
0.00%
ISIS
57.56
0.00
0.00%
LGND
103.55
-0.1
-0.10%
LPTN
2.75
-0.07
-2.48%
MBVX
5.07
-0.02
-0.34%
MEIP
1.91
-0.07
-3.54%
MNOV
6.17
-0.25
-3.89%
MRTX
5.09
+0.11
+2.21%
MSTX
0.39
-0.01
-1.49%
NBIX
49.54
+0.6
+1.23%
NUVA
64.07
+0.68
+1.07%
ONCS
1.7
-0.02
-1.16%
ONVO
3.88
-0.02
-0.51%
OREX
3.85
+0.03
+0.79%
OTIC
16.01
+0.33
+2.10%
QDEL
21.59
+0.17
+0.79%
RCPT
231.96
0.00
0.00%
RGLS
3.24
+0.08
+2.53%
RMD
69.03
+0.59
+0.86%
SPHS
3.52
+0.02
+0.57%
SRNE
6.62
+0.06
+0.91%
TROV
5
+0.08
+1.63%
VICL
3.99
+0.14
+3.64%
VOLC
18
0.00
0.00%
ZGNX
9.29
+0.21
+2.31%
Home » Archive by Category

Xconomy

MEI Pharma Partners with Helsinn on Drug with Potential $464M Payoff

August 8, 2016 – 5:00 am

After reporting encouraging news last week from a mid-stage trial of its lead anti-cancer drug, San Diego’s MEI Pharma (NASDAQ: MEIP) said it has signed a drug development deal with the Swiss…

[[Click headline to continue reading.]]

Biotech Roundup: Biogen Rumors, Theranos, Electro-Drugs & More

August 5, 2016 – 4:04 am

Biogen was once again all over the biotech newswire this week. First came a positive surprise; data that could set the stage for the first-ever drug approved for spinal muscular atrophy, a rare and…

[[Click headline to continue reading.]]

Look Beyond Football to Fight Concussions

August 2, 2016 – 8:44 am

The New York Times reported last week that the NFL and USA Football had publicized inaccurate statistics about the efficacy of a training program called Heads Up Football in preventing concussions in…

[[Click headline to continue reading.]]

Biogen Buys Ionis Spine Disease Drug For $75M, Eyes FDA Filing

August 1, 2016 – 6:07 am

Spinal muscular atrophy affects over 25,000 people in the U.S. and stops many of them from ever being able to walk. Yet scientists’ understanding of the underlying genetic cause of SMA is…

[[Click headline to continue reading.]]

Biotech Roundup: Gilead Slump, Celgene Goes Trump, Hemo Data & More

July 29, 2016 – 5:32 am

Quarterly biopharma earnings added a little heat to the already high summer temperatures. Amongst several companies to report this week, the biggest news came from Gilead Sciences (NASDAQ: GILD),…

[[Click headline to continue reading.]]

At Big Hemophilia Meeting, More Data, and Promise, For Gene Therapy

July 28, 2016 – 9:55 am

This week’s World Federation of Hemophilia World Congress in Orlando, FL, where researchers gathered to present the latest updates in treatments for the chronic bleeding disorder, marked the…

[[Click headline to continue reading.]]

LabCorp Boosts Prenatal Testing Presence with $371M Sequenom Deal

July 27, 2016 – 6:58 am

LabCorp, already a giant in diagnostics and laboratory testing, is building its capabilities in prenatal testing with an agreement to acquire Sequenom in a $371 million deal. Under the tender offer,…

[[Click headline to continue reading.]]

The Outbreaks Are Here, Where’s Our Response Plan?

July 25, 2016 – 1:32 pm

The news of the first Zika case in Pierce County—the 14th in Washington State—reminds us that the spread of disease is inevitable. While we don’t have in our region the kind of mosquito…

[[Click headline to continue reading.]]

Biotech Roundup: Scangos’s Exit, Zafgen’s Shakeup, Jounce, Relypsa & More

July 22, 2016 – 4:12 am

The top news in biotech this week centers around one big job opening: the head seat at Biogen, now that George Scangos has announced plans to leave the company. Who takes the gig, and the strategic…

[[Click headline to continue reading.]]

With Biogen at a Crossroads, CEO Scangos to Step Down

July 21, 2016 – 5:19 am

[Updated, 9:20 a.m. ET, see below] Biogen has seen its highest highs under CEO George Scangos, but some lows too. After a year in which Biogen’s share price has fallen by more than a third and one of…

[[Click headline to continue reading.]]